Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
Your view on ANIX
Overview
What the company does, where it operates, and who runs it.
About Anixa Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Amit Kumar
- Headquarters
- 3150 Almaden Expressway, San Jose, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Amit Kumar
- Headquarters
- 3150 Almaden Expressway, San Jose, CA, US
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Anixa Biosciences, Inc. from FRC's valuation model, read against the market price. ANIX last traded at $2.71; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Anixa Biosciences, Inc.. Starting points for Anixa Biosciences, Inc.: EPS -$0.30, beta 0.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Anixa Biosciences, Inc.. Anixa Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Anixa Biosciences, Inc.. Trailing twelve-month EPS for Anixa Biosciences, Inc. stands at -$0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$6.00
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy6
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJul 2019 | Next QtrApr 2021 | Current YearFY Oct 2026 | Next YearFY Oct 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.11 | -$0.11 | -$0.31 | -$0.32 |
| Low estimate | -$0.11 | -$0.11 | -$0.31 | -$0.32 |
| High estimate | -$0.11 | -$0.11 | -$0.31 | -$0.32 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | — | -$0.34 | — |
| Growth | — | — | +7.8% | — |
Revenue Estimate
| Revenue | Current QtrJul 2019 | Next QtrApr 2021 | Current YearFY Oct 2026 | Next YearFY Oct 2027 |
|---|---|---|---|---|
| Avg. estimate | $442307.00 | $605681.00 | $0.00 | $34.00M |
| Low estimate | $353845.00 | $484544.00 | $0.00 | $34.00M |
| High estimate | $530768.00 | $726817.00 | $0.00 | $34.00M |
| No. of analysts | 14 | 10 | 0 | 3 |
| Year-ago revenue | — | — | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Anixa Biosciences, Inc.. Anixa Biosciences, Inc. has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABOSAcumen Pharmaceuticals, Inc.Biotechnology$14M
- ACTUActuate Therapeutics IncBiotechnology$6M
- AGENAgenus Inc.Biotechnology$290M
- ENTXEntera Bio Ltd.Biotechnology$568M
- HURATuHURA Biosciences, Inc.Biotechnology$87M
- INOInovio Pharmaceuticals, Inc.Biotechnology$117M
- IRDOpus Genetics, Inc.Biotechnology$326M
- SEERSeer, Inc.Biotechnology$80M
More Biotechnology companies
- ONCYOncolytics Biotech Inc.NASDAQ$44M
- ONPHOncology Pharma Inc.OTC$109,553
- ONTTFOxford Nanopore Technologies plcOTC$1.8B
- OPORFhVIVO plcOTC$59M
- ORGSOrgenesis Inc.OTC$3M
- ORICORIC Pharmaceuticals, Inc.NASDAQ$795M
- ORKAOruka Therapeutics, Inc.NASDAQ$6.5B
- ORMPOramed Pharmaceuticals Inc.NASDAQ$169M
- ORPOFOSE Immunotherapeutics S.A.OTC$260M
- ORYZFOryzon Genomics S.A.OTC$284M
- OSRHWOSR Holdings, Inc.NASDAQ$8M
- OSTXOS Therapies IncorporatedAMEX$48M
ETFs holding Anixa Biosciences, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- IWCiShares Micro-Cap ETF$1.2B in assets0.02%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
- VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
- VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets0.00%
Largest holders first, then the funds most concentrated in ANIX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Anixa Biosciences, Inc., and how their positions are changing. At a $94.2M market value, institutional positions materially move Anixa Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Anixa Biosciences, Inc. executives and directors. Shares of Anixa Biosciences, Inc. have traded between $2.07 and $4.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Anixa Biosciences, Inc.. Coverage tracks Anixa Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Anixa Biosciences, Inc.